CareDx Inc

CareDx Inc. discovers develops and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart a gene expression solution for heart transplant patients; AlloSure Heart a dd-cfDNA solution for heart transplant patients; and AlloSure Lung a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr a transplant patient management software. In addition it provides AlloSeq Tx a high-resolution HLA typing solution; AlloSeq cfDNA a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions as well as AlloCare a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina Inc. for the distribution development and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx Inc. and changed its name to CareDx Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco California.